NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-EY-19-003 from the NIH Guide for Grants and Contracts
Notice NOT-EY-19-002 from the NIH Guide for Grants and Contracts
Notice NOT-EY-19-001 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-19-025 from the NIH Guide for Grants and Contracts. The purpose of this administrative supplement is to enhance data management and sharing in existing NIEHS-funded R01 grants through the integration of new expertise in data and information sciences, or knowledge management, into the research team. This initiative aims to support activities that enhance one or more aspects of research project data management, including improving the capture, storage, organization, management, integration, presentation, and dissemination of digital biomedical research data.
Notice NOT-OD-19-016 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-18-020 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for Diabetes Research Centers that are designed to support and enhance the national research effort in diabetes, its complications, and related endocrine and metabolic diseases. Diabetes Research Centers support two primary research-related activities: Research Core services and a Pilot and Feasibility (P and F) program. All activities pursued by Diabetes Research Centers are designed to enhance the efficiency, productivity, effectiveness, and multidisciplinary nature of research in Diabetes Research Center topic areas. The NIDDK Diabetes Research Centers program in 2018 consists of 16 Centers each located at outstanding research institutions with documented programs of excellence in diabetes-related research. General information about the NIDDK Diabetes Research Centers program may be found at www.diabetescenters.org.
Funding Opportunity PA-19-023 from the NIH Guide for Grants and Contracts. The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community that develop and test tools to address symptoms in caregivers. The key to this announcement is the focus on the caregiver, regardless of patient symptoms or conditions. Research is needed to enhance symptom recognition and assessment in caregivers, and to promote technological strategies to alleviate distress in caregiver symptoms. These studies are needed to advance the science related to caregiver experience of symptoms, caregiving contexts that promote these symptoms, and viable tools to address the symptoms experienced by caregivers.
Funding Opportunity PA-19-024 from the NIH Guide for Grants and Contracts. The purpose of the Funding Opportunity announcement is to encourage grant applications from the scientific community that develop and test tools to address symptoms in caregivers. The key to this announcement is the focus on the caregiver, regardless of patient symptoms or conditions. Research is needed to enhance symptom recognition and assessment in caregivers, and to promote technological strategies to alleviate distress in caregiver symptoms. These studies are needed to advance the science related to caregiver experience of symptoms, caregiving contexts that promote these symptoms, and viable tools to address the symptoms experienced by caregivers.
Notice NOT-EB-18-028 from the NIH Guide for Grants and Contracts
Notice NOT-EB-18-027 from the NIH Guide for Grants and Contracts
Notice NOT-MH-19-002 from the NIH Guide for Grants and Contracts
Notice NOT-OD-19-017 from the NIH Guide for Grants and Contracts
Notice NOT-DE-18-024 from the NIH Guide for Grants and Contracts
Notice NOT-DK-19-002 from the NIH Guide for Grants and Contracts
Notice NOT-DK-19-001 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-FD-19-001 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to support studies that advance medical product development through the characterization of the natural history of rare diseases/conditions with unmet needs. Through the support of efficient and innovative natural history studies, FDA expects to address critical knowledge gaps, to remove major barrier(s) to progress in the field, to exert a significant and broad impact on a specific rare disease or multiple rare diseases with similar pathophysiology, and to inform current or future product development including the design of clinical trial(s) and to ultimately inform the development of medical products that meet patient needs.
Notice NOT-EB-18-025 from the NIH Guide for Grants and Contracts
Notice NOT-EB-18-026 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-AA-19-004 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for specialized Alcohol Research Centers using the P50 mechanism. The overall purpose of the NIAAA Alcohol Research Center program is to provide leadership in conducting and fostering interdisciplinary, collaborative research on a wide variety of topics relevant to the Institutes mission. These topics include, but are not limited to: the nature, etiology, genetics, diagnosis, treatment, and prevention of alcohol use disorders and their biomedical, psychosocial, and economic consequences across the lifespan. Centers also are regional or national resources that contribute to the development of new research methods, technologies and approaches that sustain innovative goal-directed research
Funding Opportunity RFA-DK-18-018 from the NIH Guide for Grants and Contracts. This FOA invites applications for Clinical Centers to carefully characterize the normal course of glycemia over the entire duration of pregnancy and understand the evolution of dysglycemia when it occurs. Clinical Centers will recruit and study pregnant women starting in the first trimester and continuing at least through delivery. A separate FOA (RFA-DK-18-019) will solicit a Biostatistics Research Center. Each Clinical Center applicant will propose a study design and provide detailed information about recruitment capacity. All awardees will form a cooperative research consortium in conjunction with NIDDK to design and implement a uniform protocol. Information obtained from this study is expected to lead to improved approaches for screening for GDM, and inform the timing and approach for future clinical trials to decrease adverse perinatal outcomes and long-term sequelae of dysglycemia during pregnancy in both the mother and offspring.